DAVAC

Davac is a biotechnology company focused on the development of next-generation gene therapies using adeno-associated virus (AAV) vectors. Spun out from Touchlight Genetics, the company leverages the proprietary Doggybone DNA (dbDNA) platform to produce high-quality, synthetic DNA templates for AAV manufacturing. This approach aims to overcome the scalability and complexity challenges associated with traditional plasmid-based AAV production. Davac is currently advancing a pipeline of gene therapy candidates targeting rare genetic diseases, with the goal of providing more accessible and effective treatments for patients. By utilizing enzymatic DNA production, the company seeks to improve the safety, efficacy, and speed of gene therapy development.